Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1989-6-7
|
| pubmed:abstractText |
The sepsis syndrome represents a systemic response to infection and is defined as hypothermia (temperature less than 96 degrees F) or hyperthermia (greater than 101 degrees F), tachycardia (greater than 90 beat/min), tachypnea (greater than 20 breath/min), clinical evidence of an infection site and with at least one end-organ demonstrating inadequate perfusion or dysfunction expressed as poor or altered cerebral function, hypoxemia (PaO2 less than 75 torr), elevated plasma lactate, or oliguria (urine output less than 30 ml/h or 0.5 ml/kg body weight.h without corrective therapy). One hundred ninety-one patients with the sepsis syndrome were evaluated prospectively and comprised the placebo group of a multicenter trial of methylprednisolone in sepsis syndrome and septic shock. Forty-five percent of the patients were found to be bacteremic. Thirty-six percent of the patients were in septic shock (sepsis syndrome plus a systolic BP less than 90 mm Hg or a decrease from baseline in systolic BP greater than 40 mm Hg) on study entry. An additional 23% of the patients developed shock after admission with 70% doing so within 24 h of study entry. Shock reversal occurred with a 73% frequency. Twenty-five percent of the patients developed the adult respiratory distress syndrome (ARDS). Mortality for the patients with sepsis syndrome who did not develop shock was 13%. Mortality for the groups of patients with shock on admission and shock postadmission was 27.5% and 43.2%, respectively. Forty-seven percent of the bacteremic patients developed shock after study admission compared to 29.6% of the nonbacteremic patients (p less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0090-3493
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
389-93
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2651003-Body Temperature,
pubmed-meshheading:2651003-Double-Blind Method,
pubmed-meshheading:2651003-Hemodynamics,
pubmed-meshheading:2651003-Humans,
pubmed-meshheading:2651003-Hypotension,
pubmed-meshheading:2651003-Methylprednisolone,
pubmed-meshheading:2651003-Methylprednisolone Hemisuccinate,
pubmed-meshheading:2651003-Middle Aged,
pubmed-meshheading:2651003-Prospective Studies,
pubmed-meshheading:2651003-Random Allocation,
pubmed-meshheading:2651003-Respiratory Distress Syndrome, Adult,
pubmed-meshheading:2651003-Sepsis,
pubmed-meshheading:2651003-Shock, Septic,
pubmed-meshheading:2651003-Syndrome
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
|
| pubmed:affiliation |
Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
|
| pubmed:publicationType |
Journal Article
|